Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance

INTRODUCTION: Platinum-based chemotherapy is still the standard of care for Epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) patients after developing EGFR-TKI resistance. However, no study focusing on the role of immuno checkpoint inhibitor (ICI) based treatments f...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yujing, Jiang, Haohua, Qian, Fangfei, Chen, Ya, Zhou, Wensheng, Zhang, Yanwei, Lu, Jun, Lou, Yuqing, Han, Baohui, Zhang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230103/
https://www.ncbi.nlm.nih.gov/pubmed/37266427
http://dx.doi.org/10.3389/fimmu.2023.1161718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230103/
https://www.ncbi.nlm.nih.gov/pubmed/37266427
http://dx.doi.org/10.3389/fimmu.2023.1161718

Ejemplares similares